https://dx.doi.org/10.1001%2Fjamanetworkopen.2020.7205
Authors:
Leapman, MS, Presley, CJ, Zhu, W, Soulos, PR, Adelson, KB, Miksad, RA, Boffa, DJ, Gross, CP
Question How was programmed cell death ligand 1 (PD-L1) testing used to select immune checkpoint inhibitor treatment for patients with advanced non–small cell lung cancer (NSCLC)?
Findings In this cohort study of 45 631 patients with advanced NSCLC, substantial increases occurred in the use of first-line immune checkpoint inhibitor treatment among patients with low or negative PD-L1 expression and those without documented PD-L1 testing. These increases were consistent with the dissemination of new evidence supporting benefit in these groups.
Meaning The findings suggest that use and interpretation of the PD-L1 biomarker to guide first-line treatment for advanced NSCLC was rapidly responsive to new clinical evidence.
Sources:
JAMA Open